Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Senter

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Current Opinion in Chemical Biology|May 6, 2009
Potent antibody drug conjugates for cancer therapyPeter D Senter
Molecular Pharmaceutics|July 21, 2005
Drug carriers in medicine and biologyPeter D Senter, Jindrich Kopecek
Hematology. American Society of Hematology. Education Program|December 10, 2013
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancerJonathan G Drachman, Peter D Senter
Nature Biotechnology|September 10, 2005
Arming antibodies: prospects and challenges for immunoconjugatesAnna M Wu, Peter D Senter
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Antibody-drug conjugates for cancer therapyPaul J Carter, Peter D Senter
Nature Biotechnology|July 25, 2022
Precision cancer targeting with antibody pairsRobert T Lawrence, Peter D Senter
Proceedings of the National Academy of Sciences of the United States of America|September 3, 2016
Cutting back on the carbsVivian H Trang, Peter D Senter
Nature Biotechnology|July 12, 2012
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphomaPeter D Senter, Eric L Sievers
Molecular Pharmaceutics|January 8, 2009
Meeting report: drug carriers in medicine and biologyPeter D Senter, David A Scheinberg
Annual Review of Medicine|October 10, 2012
Antibody-drug conjugates in cancer therapyEric L Sievers, Peter D Senter
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Current Opinion in Chemical Biology|May 6, 2009
Potent antibody drug conjugates for cancer therapyPeter D Senter
Molecular Pharmaceutics|July 21, 2005
Drug carriers in medicine and biologyPeter D Senter, Jindrich Kopecek
Hematology. American Society of Hematology. Education Program|December 10, 2013
Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancerJonathan G Drachman, Peter D Senter
Nature Biotechnology|September 10, 2005
Arming antibodies: prospects and challenges for immunoconjugatesAnna M Wu, Peter D Senter
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Antibody-drug conjugates for cancer therapyPaul J Carter, Peter D Senter
Nature Biotechnology|July 25, 2022
Precision cancer targeting with antibody pairsRobert T Lawrence, Peter D Senter
Proceedings of the National Academy of Sciences of the United States of America|September 3, 2016
Cutting back on the carbsVivian H Trang, Peter D Senter
Nature Biotechnology|July 12, 2012
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphomaPeter D Senter, Eric L Sievers
Molecular Pharmaceutics|January 8, 2009
Meeting report: drug carriers in medicine and biologyPeter D Senter, David A Scheinberg
Annual Review of Medicine|October 10, 2012
Antibody-drug conjugates in cancer therapyEric L Sievers, Peter D Senter
Pageof 9